TYK Medicines Narrows Annual Loss as R&D Spending Holds Steady and Governance Changes Loom

TYK Medicines, Inc. Class H ( (HK:2410) ) has issued an announcement.

TYK Medicines reported its annual results for the year ended December 31, 2025, showing no revenue compared with a small amount in 2024, while research and development costs rose modestly to RMB244.1 million and administrative expenses declined significantly to RMB78.5 million. The company’s total comprehensive loss narrowed by 21.1% to RMB306.0 million, helped by lower administrative costs and the absence of prior-year fair value losses on redemption liabilities, indicating improved cost discipline even as it continues to invest heavily in its pipeline.

The board also announced proposed amendments to the company’s articles of association alongside the results, signaling ongoing adjustments to its corporate governance framework as it advances its development-stage strategy. For shareholders and other stakeholders, the figures underscore that TYK Medicines remains in an investment and development phase, with reduced per-share losses but still reliant on external funding until its R&D efforts translate into sustainable revenue.

The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.

More about TYK Medicines, Inc. Class H

TYK Medicines, Inc. is a PRC-incorporated biopharmaceutical company listed in Hong Kong that focuses on developing innovative medicines, with operations heavily oriented toward research and development. The company’s cost structure and financial performance are primarily driven by R&D expenditure and related administrative activities rather than commercialized product revenue at this stage.

Average Trading Volume: 2,503,292

Technical Sentiment Signal: Sell

Current Market Cap: HK$3.81B

Learn more about 2410 stock on TipRanks’ Stock Analysis page.